Human Insulin Market worth 39.13 Billion USD by 2020 Human Insulin Market worth 39.13 Billion USD by 20 | Page 17

TABLE OF CONTENTS
14 COMPANY PROFILES ............................................................................................................... 139
• ( Overview , Financials , Products & Services , Strategy , & Developments )*
• 14.1
INTRODUCTION ............................................................................................................................................................. 139
• 14.2
B . BRAUN MELSUNGEN AG ........................................................................................................................................... 143
• 14.3
BECTON , DICKINSON AND COMPANY .......................................................................................................................... 145
• 14.4
BIOCON LIMITED ........................................................................................................................................................... 148
• 14.5
BIODEL INC .................................................................................................................................................................... 151
• 14.6
ELI LILLY AND COMPANY .............................................................................................................................................. 152
• 14.7
JULPHAR ( ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES )........................................................................ 158
• 14.8
NOVO NORDISK A / S ...................................................................................................................................................... 160
• 14.9
SANOFI ........................................................................................................................................................................... 166
• 14.10
WOCKHARDT LIMITED .................................................................................................................................................. 170
• 14.11
YPSOMED AG ................................................................................................................................................................ 172
• * Details on Financials , Product & Services , Strategy , & Developments might not be captured in case of unlisted companies .
15
APPENDIX ................................................................................................................................ 175
• 15.1
INSIGHTS OF INDUSTRY EXPERTS ............................................................................................................................... 175
• 15.2
DISCUSSION GUIDE ...................................................................................................................................................... 176
• 15.3
INTRODUCING RT : REAL-TIME MARKET INTELLIGENCE .............................................................................................. 181
• 15.4
AVAILABLE CUSTOMIZATIONS ...................................................................................................................................... 181
• 15.5
RELATED REPORTS ........................................................................................................................................................ 182
•
sales @ marketsandmarkets . com www . marketsandmarkets . com
17